Currently, Immunovant Inc [IMVT] is trading at $15.00, up 2.04%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The IMVT shares have gain 6.99% over the last week, with a monthly amount glided 3.73%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Immunovant Inc [NASDAQ: IMVT] stock has seen the most recent analyst activity on March 03, 2025, when Jefferies initiated its Hold rating and assigned the stock a price target of $20. Previously, Wolfe Research downgraded its rating to Peer Perform on January 03, 2025. Oppenheimer reiterated its Outperform rating and increased its price target to $53 on October 09, 2024. Oppenheimer initiated its recommendation with a Outperform and recommended $50 as its price target on March 28, 2024. Goldman started tracking with a Buy rating for this stock on March 13, 2024, and assigned it a price target of $50. In a note dated February 20, 2024, JP Morgan initiated an Overweight rating and provided a target price of $51 on this stock.
This stock has fluctuated between a low of $12.72 and a high of $34.47 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $42.83 within the next 12 months. Immunovant Inc [NASDAQ: IMVT] shares were valued at $15.00 at the most recent close of the market. An investor can expect a potential return of 185.53% based on the average IMVT price forecast.
Analyzing the IMVT fundamentals
Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -270.14%, Pretax Profit Margin comes in at -254.78%, and Net Profit Margin reading is -255.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.91, Equity is -0.78 and Total Capital is -1.15. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Immunovant Inc [NASDAQ:IMVT] is 6.04. Also, the Quick Ratio is 6.04, while the Cash Ratio stands at 5.48.
Transactions by insiders
Recent insider trading involved GEORGE V MIGAUSKY, Former Director, that happened on May 19 ’25 when 28188.0 shares were purchased. Chief Technology Officer, Stout Jay S completed a deal on Apr 23 ’25 to sell 1925.0 shares. Meanwhile, Chief Medical Officer Geffner Michael sold 2349.0 shares on Apr 23 ’25.
